Biora: Report for the First Nine Months of 2002

STOCKHOLM, Sweden, Nov. 7, 2002 (PRIMEZONE) -- Biora AB (publ) (Other OTC:BIORY):


                                3rd Qtr    3rd   Qtr 1-   Qtr 1-   Full
                                 2002      Qtr      3     3 2001   year
                                           2001     2002            2001
Net sales, SEK million            28.1     22.0    99.5     77.8   110.7
Operating result, SEK million     -1.7    -11.5    -1.3    -26.7   -26.5
Net result, SEK million           -1.2    -11.0    -0.5    -25.7   -25.1

- Sales during the first nine months of 2002 increased by 28 percent to SEK 99.5 million (compared to SEK 77.8 million for the first nine months of 2001).

- Sales during the third quarter of 2002 increased by 28 percent to SEK 28.1 million (compared to SEK 22.0 million for the third quarter of 2001). The increase occurred primarily in the United States and Germany.

- Net result for the first nine months of 2002 was a loss of SEK 0.5 million (compared to a net loss of SEK 25.7 million for the first nine months of 2001).

- Biora will terminate its ADR program in the United States effective December 9, 2002. ADR holders may surrender their securities to the Bank of New York and receive the Ordinary Shares represented by their ADRs.

Biora develops, manufactures and sells biology-based products to dentists. Its principal product, Emdogain(R)Gel, which is approved for sale in Europe, North America and Japan among others, naturally regenerates the tooth-supporting structure that the tooth has lost due to periodontitis. Biora's American Depositary Shares are quoted on the OTC market in the U.S. and Biora's ordinary shares are listed on the "O- list" of the Stockholm Stock Exchange in Sweden.

Biora: Report for the First Nine Months of 2002

Tags